Contrave (Naltrexone HCl/Bupropion HCl) Patent Expiration, LOE Window & CMS Spending

Contrave (Naltrexone HCl/Bupropion HCl) by Azurity: FDA Orange Book LOE 2034-07-02, 0 AB generics, $1.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAzurity
FDA Application & PathwayN200063 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2034-07-02
Orange Book Patents (*PED Extensions)18 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.9M
2024 Medicare Part D Spend$1.9M
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel